Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03671018
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
- NCT03671018 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Focused
We haven't built an HCP commentary report on NCT03671018 (mosunetuzumab plus polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03671018 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab (IV); Mosunetuzumab (SC); Polatuzumab vedotin; Tocilizumab; Rituximab
- Arms
- Dose Finding · Experimental
- Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL · Experimental
- Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL · Experimental
- Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL · Experimental
- Mosunetuzumab SC + Polatuzumab Vedotin 2L+R/R DLBCL · Experimental
- Enrollment
- 422 (estimated)
- Primary outcomes
- Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin
- Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin
- Percentage of Participants with Adverse Events (AE)
- Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL
- Sponsor
- Hoffmann-La Roche
- Start
- Sep 25, 2018
- Primary completion
- Jan 30, 2024
- Results posted
- No
- Registry record
- NCT03671018 · updated Nov 29, 2024
Publications
linked from the registry- Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, Olszewski AJ, Naik S, Ghosh N, Pham S, Wei MC, Batlevi C, To I, Ead W, Makadia S, Penuel E, Jing J, Budde LE. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026 Sep;101(9):2177-2189. doi: 10.1002/ajh.70403. Epub 2026 Jun 12. PubMed 42283231
- Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026 Aug 6;148(6):682-692. doi: 10.1182/blood.2025032422. PubMed 42013019
- Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. PubMed 38072960